Multiple Sclerosis
Virtual Grand Rounds
Emerging Oral Disease –
Modifying
Therapies
for Multiple
Sclerosis
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: August 4, 2011
Expiration Date: August 4, 2012
Estimated Time of Completion: 30 minutes
Description
The purpose of this activity is to review efficacy and safety data pertaining to emerging oral disease–modifying therapies (DMTs) for use in patients with multiple sclerosis (MS).
Learning Objectives
- Describe evidence for the efficacy of emerging oral DMTs in patients with MS.
- Assess safety data for emerging oral DMTs from clinical trials including patients with MS.
- Identify patients with MS who are potential candidates for therapy with an oral DMT.
Target Audience
The target audience consists of neurologists and other healthcare professionals who manage patients with multiple sclerosis.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Alexander Rae-Grant, MD
Cleveland Clinic Neurological Institute
Mellen School for Multiple Sclerosis Treatment and Research
Cleveland Clinic
Cleveland, Ohio
Faculty
Timothy West, MD
Clinical Fellow
Department of Neurology
University of California, San Francisco
San Francisco, California
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Alexander Rae-Grant, MD |
||
| Biogen Idec | Teaching and Speaking |
|
| Novartis Pharmaceuticals Corporation | Teaching and Speaking |
|
| Teva Neuroscience, Inc. | Teaching and Speaking | |
|
||
Timothy West, MD |
||
| Biogen Idec | Independent Contractor | |
| EMD Serono, Inc. | Independent Contractor | |
| Teva Neuroscience, Inc. | Teaching and Speaking |
|
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:
Bayer HealthCare Pharmaceuticals; Biogen Idec; Teva Neuroscience, Inc.
This CME activity was produced by the
Cleveland Clinic Center for Continuing Education,
Cleveland Clinic Neurological Institute
and
